Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
silmitasertib × Gastrointestinal × Clear all
NCT02128282 2021-10-22

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Senhwa Biosciences, Inc.

Phase 1/2 Completed
127 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡